Diabetes mellitus
Adult: Dosing regimen should be individualised and adjusted based on patient's glycaemic response. Administer 15 min before or immediately after a meal.
Indications and Dosage
Subcutaneous
Diabetes mellitus Adult: Dosing regimen should be individualised and adjusted based on patient's glycaemic response. Administer 15 min before or immediately after a meal.
|
Renal Impairment
Decreased dose may be necessary.
|
Hepatic Impairment
Decreased dose may be necessary.
|
Administration
Should be taken with food. Administer w/in 15 min before or immediately after meals.
|
Contraindications
Hypoglycaemia.
|
Special Precautions
Renal or hepatic impairment; pregnancy, lactation; transferring from other insulin. Monitor serum glucose, potassium, electrolytes, HbA1c and lipid profile. Concomitant illness esp infections.
|
Adverse Reactions
Hypoglycaemia; oedema; pruritus; rash; hypersensitivity reactions; lipoatropy or lipohypertrophy with SC Inj (rotate Inj site).
|
IV/SC: B
|
Drug Interactions
Effects may be increased by: oral antidiabetic agents, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics. Effects may be decreased by: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, oral contraceptives, lithium. Signs of hypoglycaemia may be masked by β-blockers, clonidine.
|
Action
Description: Insulin lispro, a rapid-acting analog of human insulin, lowers blood glucose levels. It regulates carbohydrate, protein and fat metabolism by inhibiting hepatic glucose production and lipolysis, and enhancing peripheral glucose disposal.
Onset: 15-30 min Duration: 3-6.5 hrs. |
MIMS Class
|